Exane Derivatives’s Travere Therapeutics TVTX Stock Holding History

Exane Derivatives’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,706	Closed	-$42.6K	–	1082
2021 Q1	$42.6K	Buy	+1,706	New	+$47.1K	0.01%	532

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Exane Derivatives's TVTX Position: Q2 2021 in Review

Exane Derivatives sold out of Travere Therapeutics (TVTX) in Q2 2021, closing a stake of 1,706 shares — an estimated $42.6K sold.

Exane Derivatives first reported a position in TVTX in Q1 2021 and held it in 1 quarter. The position peaked at $42.6K in Q1 2021. 136 funds tracked by Wall St. Rank hold TVTX as of Q2 2021.

Exane Derivatives reported no remaining Travere Therapeutics position as of Q2 2021 after selling out during the quarter.
Exane Derivatives sold 1,706 Travere Therapeutics shares in Q2 2021, an estimated $42.6K.
Exane Derivatives first reported a position in Travere Therapeutics in Q1 2021 and held it in 1 quarter.
Exane Derivatives's Travere Therapeutics position peaked at $42.6K in Q1 2021.
136 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2021.

Based on Exane Derivatives's 13F filing for Q2 2021, filed 28 Jul 2021.